ULTRAGENYX
NASDAQ: RARE (Ultragenyx Pharmaceutical Inc.)
Kemas kini terakhir: semalam, 7:12AM26.90
-0.12 (-0.44%)
| Penutupan Terdahulu | 27.02 |
| Buka | 27.32 |
| Jumlah Dagangan | 1,434,076 |
| Purata Dagangan (3B) | 2,174,422 |
| Modal Pasaran | 2,649,360,128 |
| Harga / Jualan (P/S) | 4.35 |
| Harga / Buku (P/B) | 247.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| Margin Keuntungan | -93.04% |
| Margin Operasi (TTM) | -102.62% |
| EPS Cair (TTM) | -5.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 588.24% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -389.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -172.94 M |
| Pulangan Atas Aset (ROA TTM) | -24.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -377.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ultragenyx Pharmaceutical Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -1.5 |
| Purata | -1.17 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.20% |
| % Dimiliki oleh Institusi | 99.43% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |